Half of our cells and only 1 in 100 of our genes are human; the rest comprise microbes, termed the human microbiota. Over 90% of these microbes live in the large intestine. Aside from aiding food digestion, these diverse microbes can also synthesize essential vitamins or amino acids, educate and modulate the immune system response, and influence susceptibility or resistance to infections. Their potential to influence neurological conditions such as multiple sclerosis (MS) is intriguing. The overarching goal of this Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) presentation was to provide a high-level insight into gut microbiota's potential role in pediatric MS. Two specific questions were also addressed based on published work: (1) Does the gut microbiota differ between children with and without MS? and (2) Is the gut microbiota associated with future relapse risk?
Introduction

Why investigate the gut microbiota and multiple sclerosis?
Studies involving the animal model of multiple sclerosis (MS), experimental autoimmune encephalomyelitis (EAE), provided an early indication that the gut microbiota may have a major role in facilitating the onset of MS and also subsequent disease activity. [1] [2] [3] Two pivotal studies published in the same year (2011), one from the United States and one from Germany, demonstrated that mice raised in a "germfree" environment (without microbes) were less likely to develop EAE, unless re-colonized with a "normal" gut community through exposure to bedding and/or feces from conventionally raised mice. 3, 4 Furthermore, if EAE could be triggered in these germ-free mice, reduced disease activity was observed (lower clinical scores) relative to the conventionally raised mice. 3, 4 How the gut, their resident microbes, and brain communicate is not fully understood, but is an active and rapidly evolving area of inquiry. [5] [6] [7] [8] Information can flow directly between gut and brain via innervation of the vagus nerve. Other gut-brain axis connections may involve metabolites produced by microbes which enter the circulation (such as short-chain fatty acids and tryptophan metabolites); a common receptor present on both the gut and blood-brain barrier, jointly influencing their permeability; and the endocrine system. 5, 7, 8 Of particular relevance to MS is the lead role microbes play in educating the immune system and modulating immune cell differentiation.
Why gut microbiota and pediatric MS?
Pediatric MS offers a unique opportunity to explore possible triggers or modifiers of disease. Obtaining accurate lifestyle and related exposure information is facilitated by the typical close supervision offered by parents and caregivers. Furthermore, with fewer years lived, opportunity to gain clinical and biological information in close proximity to the actual onset of disease is greater relative to a typical adult presenting with MS in the third or fourth decade of life. However, major challenges include the relative rarity of pediatric MS; less than 5% of MS patients are estimated to present and receive a diagnosis in childhood. Collaborative teams such as the US Network of Pediatric MS Centers and the Canadian Pediatric Demyelinating Disease Study group are key to gathering sufficient data in order to furthering our understating of pediatric MS and the gut microbiota.
Studies exploring the gut microbiota in children with and without MS
Does the gut microbiota differ between children with and without MS?
Motivated by work in animal studies, a case-control study was initiated at the University of California, San Francisco (UCSF), USA. 9 At the time, there were no other published studies in MS and very limited information as to whether the gut microbiota had a role to play in MS. Children 18 years or younger attending a UCSF pediatric clinic were eligible for inclusion. Cases were within 2 years from MS symptom onset and all met McDonald criteria. Controls had no family history of MS or a related autoimmune disease (asthma or eczema were permissible). Stool samples were collected at home and shipped on ice to the study laboratory where they were stored at −80°C until DNA extraction and 16S rRNA gene amplification and sequencing using the Illumina Miseq platform. Overall, 18 MS cases and 17 age and sex similar controls were included. Mean age at stool sample collection was 13.0 years; the MS cases had a short disease duration, with a group mean of 10.6 months; 9/18 (50%) of cases were exposed to an MS drug (glatiramer acetate, beta-interferon or for one child, natalizumab). The initial, broad assessment of the gut microbiota composition using metrics such as alpha and beta diversity indicated that there were no significant differences between children with and without MS. However, on closer inspection at the lower, more granular taxonomic ranks, significant differences emerged. For example, for Actinobacteria, the MS children had 2.5 times the abundance of this phylum compared to the children without MS (95% confidence interval (CI): 1.3-4.9; Figure 1 ). Interestingly, this phylum has also been associated with other immune-mediated inflammatory diseases such as inflammatory bowel disease (IBD). 10 Diseasemodifying drug (DMD) exposure status was also associated with differences in the gut microbiota composition. 9 These observations are helping guide future work. For instance, it will be of value to delineate the direction of effect-did the DMD alter the gut microbiota or did the children (e.g. with more active disease) prescribed a DMD already have a different gut microbiota?
Summary. Children with MS relative to children without had subtle differences in gut microbiota which were suggestive of a "pro-inflammatory" milieu. 9 Findings might be influenced by MS drug exposure. 9 Similar observations have also now been made in adults with MS relative to controls. 5 This raises the possibility of an "MS microbiome" or a specific gut signature of MS. 11 Is the gut microbiota associated with future relapse risk? Rationale for addressing this question stems in part from animal models of MS in which alterations in the Figure 1 . Phylum-level findings (relative abundance) for cases and controls. 9 Each bar represents one child. The y-axis depicts relative abundance, reported as a proportion for each child, relative to all cases and controls. Rate ratio (shown for Actinobacteria, without covariate adjustment) was derived from the negative binomial regression. CI: confidence interval. Controls formed the reference group. gut microbiota were associated with disease activity. 3, 4 In addition, surprisingly little is known as what actually triggers or facilitates an MS relapse in humans. However, involvement of the immune system has been demonstrated, making it feasible that one of the key modulators of the immune system-the gut microbiota-could play a role in MS relapses. This study was designed as a longitudinal, prospective pilot investigation. 12 The gut microbiota composition (phylum-level abundance) was modeled as the exposure and the outcome as the first on-study MS relapse (confirmed by a neurologist). 12 The study setting and stool collection were as before, 9 with MS cases enrolled through the UCSF pediatric MS clinic; all were within 2 years from MS symptom onset at the time of the stool sample collection (see Figure 2 for the cohort characteristics). Statistical analyses were conducted in three judicious steps. First, KaplanMeier curves were used with the phylum-level relative abundance modeled as either "low versus high" (⩽ vs > median) or "absent versus present" against the time to first on-study relapse. The log-rank test was used to compare groups. Second, a conservative Bonferroni correction was applied for the multiple comparisons made. Finally, any phylum which remained significant was included in a Cox regression model, with covariate adjustment for age and DMD exposure status. Overall, 8 of the 13 phyla identified had sufficient data to be examined (i.e. detected in >20% cases). Three of eight phyla demonstrated an association, with the absence of Fusobacteria (logrank test, p = 0.001), higher abundance of Firmicutes (p = 0.003), and presence of the Archaea Euryarchaeota (p = 0.037) each associated with a higher on-study relapse risk. The latter failed a Bonferroni correction for multiple comparisons (p < 0.00625) and only the former remained significant after the multivariable Cox model was applied (hazard ratio for absence (vs presence) of Fusobacteria = 3.2; 95% CI: 1.2-9.0, p = 0.024). 12 Summary. Depletion of Fusobacteria was associated with over three times the hazard of an earlier relapse (adjusted for age and use of a MS DMD). While relatively little is known of the role of Fusobacteria, the phylum includes anaerobic, Gram-negative bacteria. Gram-negative anaerobes also belong to the Bacteroidetes phylum, such as Bacteroides fragilis. This species has been shown to play a beneficial role in EAE through polysaccharide A expression, 2 possibly by inducing differentiation of FoxP3+ regulatory T cells and interleukin (IL)-10 production. 13 Further investigation is warranted; it is possible that Fusobacteria acts through a similar pathway. Study limitations included the relative rarity of pediatric MS leading to The figure shows the characteristics of children included in the evaluation of the gut microbiota and relapse risk, 12 although all children contributed to both published studies featured in the ACTRIMS 2017 presentation. 9, 12 modest sample sizes. Consequently, the taxonomic rank assessed was broad (phylum-level) and ability for covariate adjustment was limited to two potential key confounders. Nonetheless, a better understanding of gut microbiota's role in modifying MS relapses could result in new opportunities, such as identification of novel modifiable targets which could reduce relapse risk and improve outcomes in MS. 12 Concluding remarks and future opportunities Collaborative efforts will be key in validating and extending findings in pediatric MS, 9,12,14 as well as those now published in adults with MS. 5, [15] [16] [17] [18] In particular, moving beyond identifying microbes (Who's there?) to understanding their function and addressing a central question-What are they doing?-will form an important next step. Functionality has been addressed by some (including in pediatric MS), primarily through validated algorithms such as the "Phylogenetic Investigation of Communities by Reconstruction of Unobserved States" package (PICRUSt) 19 which enables the microbe's metagenomes to be inferred (predicted) from sequencing data (16S rRNA reads). 9, 18 In addition, larger, longitudinal studies are needed to enable a better understanding and ability to model confounders, such as drug treatments, diet, gut transit time, smoking, obesity, and other lifestyle factors. The MS Society of Canada, through its MS Scientific and Research Foundation, has invested in this area, enabling a sizable biobank of stool samples from children with and without MS to be established (see acknowledgements). Collaboration is welcome in accessing this valuable resource (contact: Dr Tremlett, corresponding author). The Canadian Network is also working with the US Network supported by both the MS Society of Canada and the USA National MS Society to enable access to larger sample sizes, increased study power, and validation and replication of findings.
